Ornique (Ethinylestradiol, Etonogestrel)

The ethinylestradiol component mimics natural estrogen, while etonogestrel acts as a progestogen. Together they suppress the release of gonadotropins from the pituitary, preventing follicular development and ovulation. The progestogen also thickens cervical mucus and changes the endometrium, creating barriers to sperm and implantation.

The dosing regimen for Ornique is determined by the prescribing healthcare professional. Typically, a single vaginal ring is inserted and left in place for three weeks, followed by a one‑week ring‑free interval, but exact instructions must be provided by the prescriber.

Ornique is contraindicated in pregnancy (Category X) and must not be used by women who are pregnant or suspect they might be. It is also not recommended during breastfeeding because hormonal exposure may affect milk production and infant exposure; alternative methods should be considered.

To order Ornique, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Ornique delivers hormones via a vaginal ring, offering continuous low‑dose exposure and eliminating daily pill administration. Compared with oral combined pills, the ring provides more stable hormone levels, fewer missed‑dose risks, and a convenient three‑week wear schedule, though both share similar efficacy and safety profiles.

Ornique should be stored at ambient temperature, ideally below 25 °C. Keep the ring in its original packaging, protect it from moisture and direct sunlight, and avoid extreme temperatures to maintain product integrity.

A healthcare professional inserts the flexible vaginal ring into the upper vagina, where it remains in place for three weeks. After removal, a one‑week break follows before a new ring is inserted, providing continuous contraceptive coverage throughout the cycle.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, especially in women with pre‑existing risk factors. Other rare but severe concerns are hepatic adenoma, hypertension, and rare allergic reactions. Prompt medical attention is required if any serious symptoms develop.

Women with a history of thromboembolic disorders, uncontrolled hypertension, estrogen‑dependent tumors, active liver disease, or known hypersensitivity to the components should avoid Ornique. It is also contraindicated for smokers over 35 years of age and for those who are pregnant or suspect pregnancy.